Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44 West Wenhua Road, Jinan 250012, Shandong Province, China.
Pharmaceutical Preparation Section, Hospital of Laiwu Steel Group, Laiwu 271126, Shandong Province, China.
Biomed Pharmacother. 2016 May;80:127-135. doi: 10.1016/j.biopha.2016.03.010. Epub 2016 Mar 21.
Tumors require a blood supply for survival, growth, and metastasis. It is widely accepted that the development of the tumor microcirculation compartment need the production of new blood vessels (angiogenesis). Vasculogenic mimicry (VM) is an alternative type of blood supplement independent of endothelial vessels which refers to the formation of tumor cell-lined vessels and is associated with tumor invasion, metastasis and poor cancer patient prognosis. Although a variety of proteins and microenvironmental factors are known to contribute to VM, the mechanisms underlying its formation remain unclear. The induction of VM seems to be related to hypoxia, which may promote the plastic, transendothelial phenotype of tumor cells capable of VM. Here, with regard to the above aspects, we review the advanced research on VM including molecular mechanisms and its clinical significance; and explore the development of VM-related strategies which are being utilized for anticancer treatment.
肿瘤的存活、生长和转移都需要血液供应。人们普遍认为,肿瘤微循环腔的发育需要新血管的生成(血管生成)。血管生成拟态(VM)是一种独立于内皮血管的替代血液补充方式,指的是肿瘤细胞排列的血管的形成,与肿瘤的侵袭、转移和癌症患者不良预后有关。虽然已知多种蛋白质和微环境因素有助于 VM 的形成,但形成 VM 的机制仍不清楚。VM 的诱导似乎与缺氧有关,缺氧可能促进具有 VM 能力的肿瘤细胞的可塑性、跨内皮表型。在此,我们就 VM 的分子机制及其临床意义等方面的最新研究进行综述,并探讨了正在用于抗癌治疗的与 VM 相关策略的发展。
Biomed Pharmacother. 2016-3-21
J Cell Mol Med. 2015-2
Biomed Pharmacother. 2017-12-6
J Cell Mol Med. 2016-9
J Hematol Oncol. 2020-3-14
Clin Cancer Res. 2012-4-2
Mol Cancer. 2017-3-21
Mol Cancer. 2021-1-4
World J Gastrointest Oncol. 2025-6-15
Cell Mol Life Sci. 2024-4-18
Front Pharmacol. 2024-3-21
J Biomed Sci. 2022-11-18
Cancer Metastasis Rev. 2022-12